Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.
Sangle
Shirish R
SR
Hughes
Graham R V
GR
D'Cruz
David P
DP
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab